Down-regulation of survivin alleviates experimental arthritis

Journal of Leukocyte Biology

Volumn 97, Issue 1, 2015, Pages 135-145

  Andersson, K M E ^a   Svensson, M N D ^a   Erlandsson, M C ^a   Jonsson, I M ^a   Bokarewa, M I ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Blimp 1; Erosions; P53; Synovitis; T cells; Treg

Indexed keywords

B LYMPHOCYTE INDUCED MATURATION PROTEIN 1; BETA CATENIN; INTERLEUKIN 2; METALLOPROTEINASE; PROTEIN P53; SHORT HAIRPIN RNA; SURVIVIN; VIMENTIN; BIRC5 PROTEIN, MOUSE; INHIBITOR OF APOPTOSIS PROTEIN; REPRESSOR PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE INJURY; BONE METABOLISM; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; EXPERIMENTAL ARTHRITIS; FEMALE; KNEE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SYNOVIAL FLUID; SYNOVIUM; T LYMPHOCYTE; ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; DBA MOUSE; FLOW CYTOMETRY; GENE SILENCING; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; MALE; METABOLISM; RHEUMATOID ARTHRITIS; WESTERN BLOTTING;

LENTIVIRUS; MUS;

ANIMALS; ARTHRITIS, EXPERIMENTAL; ARTHRITIS, RHEUMATOID; BLOTTING, WESTERN; DOWN-REGULATION; FEMALE; FLOW CYTOMETRY; GENE KNOCKDOWN TECHNIQUES; IMMUNOHISTOCHEMISTRY; INHIBITOR OF APOPTOSIS PROTEINS; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED DBA; REPRESSOR PROTEINS;

EID: 84925286639     PISSN: 07415400     EISSN: 19383673     Source Type: Journal    
DOI: 10.1189/jlb.3A0714-317R     Document Type: Article

References (66)

1. Eriksson, J. K., Ncovius, M., Erncstam, S., Lindblad, S., Simard, J. F., Askling, J. (2013) Incidence of rheumatoid arthritis in Sweden: a nationwide population-based assessment of incidence, its determinants, and treatment penetration. Arthritis Care firs. (Hoboken) 65, 870-878.
2. Bokarewa, M., Brink, M., Erlandsson, M., Rantapää Dahlqvist, S. (2014) Survivin but not Fms-like tyrosine kinase 3 ligand is up-regulated before the onset of rheumatoid arthritis: a pilot study. Arthritis Res. Ther. 16, R45.
3. Altieri, D. C. (2008) Survivin, cancer networks and pathway-directed drug discovery. Nat. Rev. Canrer 8, 61-70.
4. Small, S., Keerthivasan, G., Huang, Z., Gurbuxani, S., Crispino, J. D. (2010) Overexpression of survivin initiates hematologic malignancies in vivo. Isukemia 24, 1920-1926.
5. Fukuda, S., Peius, I,. M. (2006) Survivin, a cancer target with an emerging role in normal adult tissues. Mot. Cancer Ther. 5, 1087-1098.
6. Ahn, J. K., Oh.J. M., l.ee, J., Bae, E. K., Ahn, K. S., Cha, H. S., Koh, E. M. (2010) Increased extracellular survivin in the synovial fluid of rheumatoid arthritis patients: fibroblast-like synoviocytes as a potential source of extracellular survivin. Inflammation 33, 381-388.
7. Park, M. C., Chung, S. J., Park, Y. B., Lee, S. K. (2008) Relationship of angiogenic factors to disease activity and radiographic damage in rheumatoid arthritis. Clin. Exp. Rheumatol. 26, 881-886.
8. Dharmapatni, A. A., Smith, M. D., Findlay, D. M., Holding, C. A., Evdokiou, A., Ahern, M. J., Weedon, H., Chen, P., Screaton, G., Xu, X. N., Haynes, D. R. (2009) Elevated expression of caspase-3 inhibitors, survivin and xIAP correlates with low levels of apoptosis in active rheumatoid synovium. Arthritis Res. Ther. 11, R13.
9. Smith, M. D., Weedon, H., Papangelis, V., Walker, J., Roberts-Thomson, P. J., Ahern, M. J. (2010) Apoptosis in the rheumatoid arthritis synovial membrane: modulation by disease-modifying anti-rheumatic drug treatment. Rheumatology (Oxford) 49, 862-875.
10. Baran, M., Möllers, I,. N., Andersson, S., Jonsson, I. M., Ekwall, A. K., Bjersing, J., Tarkowski, A., Bokarewa, M. (2009) Survivin is an essential mediator of arthritis interacting with urokinase signalling. J. Cell. Mol. Med. 13, 3797-3808.
11. Bokarewa, M., Lindblad, S., Bokarew, D., Tarkowski, A. (2005) Balance between survivin, a key member of the apoptosis inhibitor family, and its specific antibodies determines erosivity in rheumatoid arthritis. Arthritis Res. Ther. 7, R349-R358.
12. Svensson, B., Hafström, I., Forslind, K., Albertsson, K., Tarkowski, A., Bokarewa, M. (2010) Increased expression of proto-oncogene survivin predicts joint destruction and persistent disease activity in early rheumatoid arthritis. Ann. Med. 42, 45-54.
13. Svensson, B., Hafström, I., Erlandsson, M. G., Forslind, K., Bokarewa, M. I. (2014) Smoking in combination with antibodies to cyclic ciunllinated peptides is associated with persistently high levels of survivin in early rheumatoid arthritis: a prospective cohort study. Arthritis Res. Ther. 16, R12.
14. Singh, P., Hoggatt, J., Hu, P., Speth.J. M., Fukuda, S., Breyer, R. M., Peius, L. M. (2012) Blockade of prostaglandin F.2 signaling through FPI and FP3 receptors attenuates FltiU.-dependent dendritic cell development from hematopoietic progenitor cells. Blood 119, 1671-1682.
15. Andersson, S. F., Svensson, M. N., Erlandsson. M. C., Dehlin, M., Andersson, K. M., Bokarewa, M. I. (2012) Activation of Fms-like tyrosine kinase 3 signaling enhances survivin expression in a mouse model of rheumatoid arthritis. PLoS ONE 7, c47668.
16. Okada, H., Bakal, C., Shahinian, A., F.lia, A., Wakeham, A., Suh, W. K., Duncan, G. S., Ciofani, M., Rottapel, R., Zúñiga-Pflücker, J. C., Mak, T. W. (2004) Survivin loss in thymocytes triggere p53-mediated growth arrest and p53-independent cell death. J Exp. Med. 199, 399-410.
17. Xing, Z., Conway, E. M., Kang, C., Winoto, A. (2004) Essential role of survivin, an inhibitor of apoptosis protein, in T cell development, maturation, and homeostasis. J Exp. Med. 199, 69-80.
18. Song, J., So, T., Croft, M. (2008) Activation of NF-kappaBl by 0X40 contributes to antigen-driven T cell expansion and survival. J. ImmunoL 180, 7240-7248.
19. Komacker, M., Verneris, M. R., Kornacker, B., Scheffold, C., Negrin, R. S. (2001) Survivin expression correlates with apoptosis resistance after lymphocyte activation and is found preferentially in memory T cells. Immunol. Lett. 76, 169-173.
20. Courtenay, J. S., Dallman, M. J., Dayan, A. D., Martin, A., Mosedale, B. (1980) Immunisation against heterologous type II collagen induces arthritis in mice. Nature 283, 666-668.
21. Brackedz, D., Mitchell, G. F., Vadas, M. A., Mackay, I. R., Miller, J. F. (1977) Studies on antigen-induced arthritis in mice. II. Immunologic correlates of arthritis susceptibility in mice. J Immunol. 118, 1639-1644.
22. Dehlin, M., Andersson, S., Erlandsson, M., Brissleit, M., Bokarewa, M. (2011) Inhibition of fms-like tyrosine kinase 3 alleviates experimental arthritis by reducing formadon of dendritic cells and antigen presentation. J. Leukoc. Biol. 90, 811-817.
23. Lindblad, S. S., Mydel, P., Jonsson, I. M., Senior, R. M., Tarkowski, A., Bokarewa, M. (2009) Smoking and nicodne exposure delay development of collagen-induced arthritis in mice. Arthritis Res. Ther. 11, R88.
24. Verdrengh, M., Jonsson, I. M., Holmdahl, R., Tarkowski, A. (2003) Genistein as an anti-inflammatory agent. Inflamm. Res. 52, 341-346.
25. Svensson, M. N., Andersson, S. E., Erlandsson, M. C., Jonsson, I. M., Ekwall, A. K., Andersson, K. M., Nilsson, A., Bian, L., Brisslert, M., Bokarewa, M. I. (2013) Fms-like tyrosine kinase 3 ligand controls formadon of regulatory T cells in autoimmune arthritis. PLoS ONE 8, e54884.
26. Takaishi, H., Kimura, T., Dalai, S., Okada, Y., D'Armiento, J. (2008) Joint diseases and matrix metalloproteinases: a role for MMP-13. Curr. Pharm. Biotechnol. 9, 47-54.
27. Tang, I., Ling, X., Liu, W., Das, G. M., Li, F. (2012) Transcriptional inhibition of p21WAFl/CIPl gene (CDKN1) expression by survivin is at least partially p53-lependent: evidence for survivin acting as a transcription factor or co-factor. Biochem. Biophys. Res. Commun. 421, 249-254.
28. Martins, G., Clame, K. (2008) Regulation and functions of Blimp-1 in T and B lymphocytes. Annu. Rev. Immunol. 26, 133-169.
29. Shin, H., Blackburn, S. D., Indekofer, A. M., Kao, C, Angelosanto, J. M., Reiner, S. I., Wherry, E. J. (2009) A role for the transcriptional repressor Blimp-1 in CD8(+) T cell exhaustion during chronic viral infection. Immunity 31, 309-320.
30. Kallies, A., Xin, A., Belz., G. T., Nutt, S. L. (2009) Blimp-I transcription factor is required for the differentiation of effector CD8(+) T cells and memory responses. Immunity 31, 283-295.
31. Khan, O. M., Ibrahim, M. X., Jonsson, I. M., Karlsson, C., Uu. M., Sjogren, A. K., Olofsson, F. J., Brisslert, M., Andersson, S., Ohlsson, C., Hulten, L. M., Bokarewa, M., Bergo, M. O. (2011) Geranylgeranyltransferase type I (GGTase-I) deficiency hyperactivates macrophages and induces erosive arthritis in mice. J. Clin. Invest. 121, 628-639.
32. Tak, P. P., Smeets, T. J., Daha, M. R., Kluin, P. M., Meijers, K. A., Brand, R., Meinders, A. E., Breedveld, F. C. (1997) Analysis of the synovial cell infiltrate in early rheumatoid synovial tissue in relation to local disease activity. Arthritis Rheum. 40, 217-225.
33. Ley, K., Uiudanna, C., Cybulsky, M. I., Nourshargh, S. (2007) Getting to the site of inflammation: the leukocyte adhesion cascade updated. Nat. Rev. Immunol. 7, 678-689.
34. Herter, J., Zarbock, A. (2013) Integrin regulation during leukocyte recruitment. J Immunol. 190, 4451-4457.
35. Pullerits, R., Brisslert, M., Jonsson, I. M., Tarkowski, A. (2006) Soluble receptor for advanced glycation end products triggers a proinflammatory cytokine cascade via beta2 integrin Mac-1. Arthritis Rheum. 54, 3898-3907.
36. Tezcan, O., Gimdiiz, U. (2014) Vimentin silencing effect on invasive and migration characteristics of doxorubicin resistant MCF-7 cells, liiomed. Phamacother. 68, 357-364.
37. Lee, L. K., Bryant, K.J., Bouveret, R., Lei, P. W., Duff, A. P., Harrop, S.J., Huang, F. P., Harvey, R. P., Gelb, M. H., Gray, P. P., Curmi, P. M., Cunningham, A. M., Church, W. B., Scott, K. F. (2013) Selective inhibition of human group ILA-secreted phospholipasc A2 (hGILA) signaling reveals arachidonic acid metabolism is associated with colocalization of hGIlA to vimentin in rheumatoid synoviocytes. J. Biol. Chem. 288, 15269-15279.
38. Lefevre, S., Knedla, A., Tennie, C., Kampmann, A., Wunrau, C., Dinser, R., Korb, A., Schnaker, F,. M., Tamer, I. H., Robbins, P. D., Evans, C. H., Sturz, H., Steinmeyer, J., Gay, S., Scholmerich, J., Pap, T., Miillci-l.adner, U., Neumann, E. (2009) Synovial fibroblasts spread rheumatoid arthritis to unaffected joints. Nat. Med. 15, 1414-1420.
39. Zen, K., Chen, C. X., Chen, Y. T., Wilton, R., Liu, Y. (2007) Receptor for advanced glycation endproducts mediates neutrophil migration across intestinal epithelium. J. Immunol. 178, 2483-2490.
40. Ma, H., Nguyen, G, Lee, K. S., Kahn, M. (2005) Differential roles for the coactivators CBP and p300 on TCF/beta-catenin-mediated survivin gene expression. Oncogene 24, 3619-3631.
41. Lories, R. J., Corr, M., lane, N. E. (2013) To Wnt or not to Wnt: the bone and joint health dilemma. Nat. Rev. Rheumatol. 9, 328-339.
42. Sen, M., I.auterbach, K., El-Gabalawy, H., Firestein, G. S., Corr, M., Carson, D. A. (2000) Expression and function of wingless and frizzled homologs in rheumatoid arthritis. Proc. Natl. Acad. Sei. USA 97, 2791-2796.
43. Ma, B., van Blitterswijk, C. A., Karperien, M. (2012) A Wnt/ß-catenin negative feedback loop inhibits interleukin-l-induced matrix metalloproteinase expression in human articular chondrocytes. Arthritis Rheum. 64, 2589-2600.
44. Walsh, N. C., Reinwald, S., Manning, C. A., Condon, K. W., Iwata, K., Burr, D. B., Gravallese, E. M. (2009) Osteoblast function is compromised at sites of focal bone erosion in inflammatory arthritis. J. Bone Minor. Res. 24, 1572-1585.
45. Sen, M., Chamorro, M., Reifert, J., Corr, M., Carson, D. A. (2001) Blockade of Wnt-5A/frizzled 5 signaling inhibits rheumatoid synoviocyte activation. Arthritis Rheum. 44, 772-781.
46. Hill, T. P., Später, D., Taketo, M. M., Birchmeier, W., Hartmann, C. (2005) Canonical Wnt/beta-catenin signaling prevents osteoblasts from differentiating into chondrocytes. Dev. Cell 8, 727-738.
47. McCarthy, T. L., Centrella, M. (2010) Novel links among Wnt and TGF- beta signaling and Runx2. Mol. Endocrinol. 24, 587-597.
48. Inada, M., Wang, Y., Byrne, M. H., Rahman, M. U., Miyaura, C., López- Otin, C., Krane, S. M. (2004) Critical roles for collagenase-3 (Mmp13) in development of growth plate cartilage and in endochondral ossification. Pmc. Natl. Acad. Sei. USA 101, 17192-17197.
49. Stickens, D., Behonick, D. J., Ortega, N., Heyer, B., Hartenstein, B., Yu, Y, Fosang, A. J., Schorpp-Kistner, M., Angel, P., Werb, Z. (2004) Altered endochondral bone development in matrix metalloproteinase 13-dcficient mice. Development 131, 5883-5895.
50. Martignetti, J. A., Aqeel, A. A., Sewairi, W. A., Boumah, C. E., Kambouris, M., Mayouf, S. A., Sheth, K. V., Eid, W. A., Dowling, O., Harris, J., Glucksman, M. J., Bahabri, S., Meyer, B. F., Desnick, R. J. (2001) Mutation of the matrix metalloproteinase 2 gene (MMP2) causes a multicentric osteolysis and arthritis syndrome. Nat. Genet. 28, 261-265.
51. Chen, X. Q., Yang, S., Li, Z. Y., Lu, H. S., Kang, M. Q., Un, T. Y. (2012) Effects and mechanism of downregulation of survivin expression by RNA interference on proliferation and apoptosis of lung cancer cells. Mol. Med. Rep. 5, 917-922.
52. Gou, X., Yang, H. A., He, W. Y., Xioa, M. C., Wang, M. (2011) Gene silence-induced downregulation of survivin inhibits bladder cancer cells. Oncol. Res. 19, 535-541.
53. Beltrami, E., Plescia, J., Wilkinson, J. C., Duckett, C. S., Altieri, D. C. (2004) Acute ablation of survivin uncovers p53-dependent mitotic checkpoint functions and control of mitochondrial apoptosis. J. Biol. Chem. 279, 2077-2084.
54. Yang, D., Welm, A., Bishop, J. M. (2004) Cell division and cell survival in the absence of survivin. Proc. Natl. Acad. Sri. USA 101, 15100-15105.
55. Fukuda, S., Mantel, C. R., Peius, L. M. (2004) Survivin regulates hematopoietic progenitor cell proliferation through p21WAFl/Cipl- dependent and -independent pathways. Blood 103, 120-127.
56. Damalas, A., Kahan, S., Shtutman, M., Ben-Ze'ev, A., Oren, M. (2001) Deregulated beta-catenin induces a p53- and ARF-dependent growth arrest and cooperates with Ras in transformation. EMBO J. 20,4912-4922.
57. Rutishauser, R. I., Martins, G. A., Kalachikov, S., Chandele, A., Parish, I. A., Meffre, E., Jacob, J., Calame, K., Kaech, S. M. (2009) Transcriptional repressor Blimp-1 promotes CD8(+) T cell terminal differentiation and represses the acquisition of central memory T cell properties. Immunity 31, 296-308.
58. Wright, G. P., Notley, C. A., Xue, S.-A., Bendle, G. M., Holler, A., Schumacher, T. N., Ehrenstein, M. R., Stauss, H. J. (2009) Adoptive therapy with redirected primary regulatory T cells results in antigen-specific suppression of arthritis. Proc. Natl. Acad. Set. USA 106, 19078-19083.
59. Morgan, M. E., Sutmuller, R. P. M., Witteveen, H.J., van Duivenvoorde, L. M., Zanclli, E., Melief, C.J. M,, Snijders, A., Offringa, R., de Vries, R. R. P., Toes, R. E. M. (2003) CD25+ cell depletion hastens the onset of severe disease in collagen-induced arthritis. Arthritis Rheum. 48, 1452-1460.
60. Kong, N., Lan, Q., Chen, M., Zheng, T., Su, W., Wang, J., Yang, Z., Park, R., Dagliyan, G., Conti, P. S., Brand, D., Liu, Z., Zou, H., Stohl, W., Zheng, S. G. (2012) Induced T regulatory cells suppress osteoclastogenesis and bone erosion in collagen-induced arthritis better than natural T regulatory cells. Ann. Rheum. Dis. 71, 1567-1572.
61. Zaiss, M. M., Sarter, K., Hess, A., Engelke, K., Bohm, C., Nimmerjahn, F., Voll, R., Schett, G., David, J.-P. (2010) Increased bone density and resistance to ovariectomy-induced bone loss in FoxP3-transgenic mice based on impaired osteoclast differentiation. Arthritis Rheum. 62, 2328-2338.
62. Takeshita, S., Kaji, K, Kudo, A. (2000) Identification and characterization of the new osteoclast progenitor with macrophage phenotypes being able to differentiate into mature osteoclasts. J. Bone Miner. Res. 15, 1477-1488.
63. Sato, K., Sucmatsu, A., Okamoto, K, Yamaguchi, A., Morishita, V., Kadono, Y., Tanaka, S., Kodama, T., Akira, S., Iwakura, Y., Cua, D. J., Takayanagi, H. (2006) Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction. J Exp. Med. 203, 2673-2682.
64. Adamopoulos, I. E., Chao, C. C., Geissler, R., Laface, D., Blumenschein, W., Iwakura, Y., McClanahan, T., Bowman, E. P. (2010) Interleukin-17A upregulates receptor activator of NF-kappaB on osteoclast precursors. Arthritis Res. Ther. 12, R29.
65. Nishikawa, K, Nakashima, T., Hayashi, M., Fukunaga, I., Kato. S., Kodama, T., Takahashi, S., Calame, K., Takayanagi. H. (2010) Blimpl-mcdiatcd repression of negative regulators is required for osteoclast differentiation. Pmc. Natl. Acad. Sci. USA 107, 3117-3122.
66. Miyauchi, Y., Ninomiya, K., Miyamoto, H., Sakamoto, A., Iwasaki, R., Hoshi, H., Miyamoto, K., Hao, W., Yoshida, S., Morioka, H., Chiba, K., Kato, S., Tokuhiso, T., Saitou, M., Toyama, Y., Suda, T., Miyamoto, T. (2010) The Blimpl-Bcl6 axis is critical to regulate osteoclast differentiation and bone homeostasis. J. Exp. Med. 207, 751-762.